Quest To Acquire Celera for $671M
Date: 2011-05-12
Quest Diagnostics agreed Friday to acquire Celera Corp. as the company seeks to expand in gene-based medical testing.
Quest Diagnostics, Inc. announced on Friday that the company will acquire Celera Corp. for $671 million, providing Quest with access to genetic tests and an R&D pipeline focused on cardiovascular disease and cancer. The transaction is expected to close the end of April.
Celera focuses on sequencing the human genome and identifying links between genetic variations and disease states. Quest also recently announced plans to acquire the Athena Diagnostics business from Thermo Fisher Scientific Inc. for $740 million in cash. Athena is a provider of diagnostic tests for neurological conditions, including Alzheimer's disease.
